Long-term use of progestogens - Effects on endometriosis, adenomyosis and myomas

Gynecological Endocrinology

Volumn 23, Issue SUPPL. 1, 2007, Pages 17-21

  Schweppe, Karl Werner ^a,b  

^a Ammerland Klinik GmbH   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Adenomyosis; Endometriosis; Long term treatment; Medical treatment; Progestogens; Uterine myomas

Indexed keywords

DANAZOL; DESOGESTREL; DIENOGEST; DYDROGESTERONE; ESTROGEN; ETHINYLESTRADIOL; FOLLITROPIN; GESTAGEN; GONADORELIN; GOSERELIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; LEUPRORELIN; LEVONORGESTREL; LUTEINIZING HORMONE; LYNESTRENOL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; STEROID RECEPTOR;

ADENOMYOSIS; BLEEDING; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ENDOMETRIOSIS; ENDOMETRIUM; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MITOSIS; MODULATION; MONOTHERAPY; MYOMA; MYOMETRIUM; PAIN; PARACRINE SIGNALING; PREGNANCY; PREGNANCY RATE; PRIORITY JOURNAL; RECURRENT DISEASE; TISSUE DISTRIBUTION;

ENDOMETRIOSIS; FEMALE; HUMANS; MYOMA; PROGESTINS;

EID: 35349010991     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701584923     Document Type: Conference Paper

References (33)

1. Hammond CB, Haney AF. Conservative treatment of endometriosis. Fertil Steril 1978;30:497-509.
2. Kauppila A, Rönnberg L, Viehko R. Steroidrezeptoren in endometrischem. Gewebe Endometriose 1986;4:56-59.
3. Vierikko P, Kauppila A, Rönnberg L, Viehko R. Steroidal regulation of endometriosis tissue. Fertil Steril 1985;43:218-223.
4. Obolensky W, Kamber J. Therapie der Endometriose mit Dydrogesteron in Depot form. Ther Umsch 1973;30:558-562.
5. Schweppe K-W. Klinik und Morphologie der Endometriose. Stuttgart: Schattauer; 1984. pp 133-150.
6. Zeitoun KM, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, Johns A, Putman M, Carr B, Bulun SE. Deficient 17β-hydroxysteroid dehydrogenase type 2 expression in endometriosis. Failure to metabolize 17β-estradiol. J Clin Endocrinol Metab 1998;83:4474-4478.
7. Attar E, Bulun SE. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Human Reprod Update 2006;12:49-56.
8. Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N. Progesterone and progestational compounds attenuate tumor necrosis factor α-induced interleukin-8 production via nuclear factor κB inactivation in endometriotic stromal cells. Fertil Steril 2005;83:1530-1535.
9. Timmonen S, Johansson CJ. Endometriosis treated with lynestrenol. Ann Chir Gynaecol 1968;57:144-147.
10. Andrews MC, Andrews WC, Strauss AF. Effects of progestin induced pseudopregnancy on endometriosis: clinical and microscopic studies. Am J Obstet Gynecol 1959;78:776.
11. Seliger E, Kaltwasser P, Schneider F, Rothe K, Röpke F. Behandlung der Endometriose mit Dienogest - Einfluss auf den Rezeptorstatus im Endometrium und vergleichende Bindungsstudien. In: Teichmann AT, editor. Dienogest - Präklinik und Klinik eines Gestagens. Berlin: W. de Gruyter Verlag; 1995. pp 231-243.
12. Telimaa S, Puolakka J, Rönnberg I, Kauppila A. Placebo controlled comparison of danazol and high dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1987;1:13-19.
13. Schweppe K-W. Einsatz der Gestagene zur Behandlung der Endometriose - Medrogeston versus Danazol. In: Schindler AE, Ebert Ch, editors. Menopause aktuell. Basel: Aesopus; 1996. pp 85-93.
14. Vercellini P, Trespidi L, Vendola N. A gonadotropin releasing hormone agonist versus a low dose OC for pelvic pain associated with endometriosis. Fertil Steril 1993;60:75-79.
15. Regidor PA, Regidor M, Schmidt M, Ruwe B, Lübben G, Förtig P, Kienle E, Schindler AE. Prospective randomised study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol 2000;14:1-8.
16. Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 2005;20:789-793.
17. Schweppe K-W. GnRH analogues: state of the art. In: Lunenfeld B, Insler V, editors. GnRH analogues. Carnforth (UK): Parthenon Publishing Group; 1996. pp 83-94.
18. Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997;68:393-401.
19. Wood C. Surgical and medical treatment of adenomyosis. Hum Reprod Update 1998;4:323-336.
20. Buttram VC, Reiter RS. Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 1981;36:433-442.
21. Townsend DE, Sparkes RS, Baluda MC, McClelland G. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 1970;107:1168-1173.
22. Nibert M, Heim S. Uterine leiomyoma cytogenetics. Genes Chromosomes Cancer 1990;2:3-13.
23. Rein MS, Friedman AJ, Barbieri RL. Cytogenic abnormalities in uterine leiomyomata. Obstet Gynecol 1991;77:923-926.
24. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995;172:14-18.
25. Kawaguchi D, Fujii S, Konishi I, Nanbu Y, Nonagaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989;160:637-641.
26. Amminen S, Rantala I, Helin H, Rorarius M, Tuimala R. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol Obstet Invest 1992;34:111-114.
27. Harrison-Woolrych ML, Charnock-Jones DS, Smith SK. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab 1994;78:1179-1184.
28. Brandon DD, Bethea CL, Strawn EY. Progesterone receptor messenger ribonucleic acid and protein are over expressed in human uterine leiomyomas. Am J Obstet Gynecol 1993;169:78-85.
29. Buchi KA, Keller PJ. Cytoplasmic progestin receptors in myomal and myometrial tissues. Concentrations and hormonal dependency. Acta Obstet Gynecol Scand 1983;62:487-492.
30. Vij U, Murugesan K, Laumas KR, Farooq A. Progestin and antiprogestin interactions with progesterone receptors in human myomas. Int J Gynaecol Obstet 1990;31:347-353.
31. Segaloff A, Weed JC, Sternberg WH, Parson W. The progesterone therapy of human uterine leiomyomas. J Clin Endocrinol Metab 1949;9:1273-1291.
32. Mixson WT, Hammond DO. Response of fibromas to a progestin. Am J Obstet Gynecol 1961;82:754-760.
33. Maheux R. Treatment of fibroids with the combination of the GnRH agonist goserelin (Zoladex) and hormone replacement therapy. In: Shaw RW, editor. Advances in reproductive endocrinology: Uterine fibroids, time for review. Carnforth (UK): Parthenon Publishing Group; 1992. pp 135-146.